These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32912879)

  • 1. Paraprotein associated syndrome treated successfully with chemotherapy.
    Gurung R; Robertson C; Vickers MA
    BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32912879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature.
    Gomez A; Hoffman JE
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):e101-8. PubMed ID: 27245314
    [No Abstract]   [Full Text] [Related]  

  • 3. Delayed development of the IgM paraprotein in Schnitzler's syndrome.
    Mulla E; Neame R
    Scand J Rheumatol; 2015; 44(6):521-2. PubMed ID: 26395927
    [No Abstract]   [Full Text] [Related]  

  • 4. Bilateral primary adrenal lymphoma successfully treated with non-CHOP chemotherapy regimen.
    Singh A; Udupa K; Madhyastha SP; Sharma S
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30108114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.
    Manwani R; Sachchithanantham S; Mahmood S; Foard D; Sharpley F; Rezk T; Lane T; Quarta C; Fontana M; Lachmann HJ; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
    Blood; 2018 Aug; 132(7):761-764. PubMed ID: 29925500
    [No Abstract]   [Full Text] [Related]  

  • 6. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
    Liu Z; Markham M; Mandernach MW
    BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20.
    Alrifai T; Grant Szymanski K; Venugopal P; Mahon B; Okwuosa T; Karmali R
    Chemotherapy; 2017; 62(2):140-146. PubMed ID: 27960150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness.
    Chen LY; Keddie S; Lunn MP; Bomsztyk J; Vitsaras E; Gupta R; D'Sa S
    Br J Haematol; 2020 Feb; 188(4):511-515. PubMed ID: 31588566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
    Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
    Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
    Rummel MJ; Janssens A; MacDonald D; Keating MM; Zaucha JM; Davis J; Lasher J; Babanrao Pisal C; Izquierdo M; Friedberg JW
    Br J Haematol; 2021 Jun; 193(6):1123-1133. PubMed ID: 33973233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
    Gyan E; Sonet A; Brice P; Anglaret B; Laribi K; Fruchart C; Tilly H; Araujo C; Soubeyran P; Gonzalez H; Morineau N; Nicolas-Virelizier E; Ghesquières H; Salles B; Bouabdallah R; Orfeuvre H; Fahri J; Couturier O; Xerri L; Feugier P;
    Br J Haematol; 2018 Oct; 183(1):76-86. PubMed ID: 30117149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A woman with recurrent urticaria, joint pain and fever].
    Gran JT; Midtvedt Ø; Haug S
    Tidsskr Nor Laegeforen; 2011 Jan; 131(2):135-6. PubMed ID: 21267032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases.
    Eren R; Suyanı E
    Turk J Haematol; 2018 Nov; 35(4):312-313. PubMed ID: 29983407
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
    N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
    Hitz F; Zucca E; Pabst T; Fischer N; Cairoli A; Samaras P; Caspar CB; Mach N; Krasniqi F; Schmidt A; Rothermundt C; Enoiu M; Eckhardt K; Berardi Vilei S; Rondeau S; Mey U
    Br J Haematol; 2016 Jul; 174(2):255-63. PubMed ID: 27018242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presentation and management of the delayed type of hypersensitivity reaction with bendamustine.
    Shikdar S; Totton D; Turco T; Rachshtut M
    Anticancer Drugs; 2018 Sep; 29(8):814-816. PubMed ID: 29877929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
    Kambhampati S; Fakhri B; Ai WZ; Kaplan LD; Tuscano JM; Wieduwilt MJ; Sudhindra A; Cavallone E; Reiner J; Aoun C; Castillo M; Martinelli M; Ta T; Le D; Padilla M; Crawford E; Andreadis CB
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):139-146. PubMed ID: 33478921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.